Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 24;2(2):e000059.
doi: 10.1136/bmjno-2020-000059. eCollection 2020.

May lamotrigine be an alternative to topiramate in the prevention of migraine with aura? Results of a retrospective study

Carmelo Luca Smeralda  1   2 , Gian Luigi Gigli  1   3 , Francesco Janes  1 , Mariarosaria Valente  1   2
Affiliations

May lamotrigine be an alternative to topiramate in the prevention of migraine with aura? Results of a retrospective study

Carmelo Luca Smeralda et al. BMJ Neurol Open. .

Abstract

Background: Evidence suggests that lamotrigine could be effective in reducing aura frequency and duration. However, studies comparing lamotrigine to other, first-line prophylactic agents solely involving patients suffering from migraine with aura are still lacking. The aim of this study was to compare the efficacy of lamotrigine and topiramate for the preventive treatment of migraine with aura.

Methods: Fifty-three patients suffering from migraine with aura treated with lamotrigine or topiramate for at least 6 months were included. Pre- and post-treatment clinical data regarding monthly aura frequency and duration, monthly migraine frequency, days of headache and rescue medication used per month were collected.

Results: Responder rates were similar between the two treatment groups at 6-month follow-up. Interestingly, responder rates for aura frequency and duration were higher in the lamotrigine group compared with the topiramate group (88% vs 79% and 73% vs 54%). Moreover, 50% of the lamotrigine-treated patients reported a complete disappearance of migraine aura compared with 37% of topiramate-treated patients. Side effects were more frequent in topiramate group compared with lamotrigine group (p=0.004).

Conclusions: Lamotrigine should be considered in clinical practice for the preventive treatment of migraine with aura especially for patients reporting prolonged aura and who do not respond, have contraindications or discontinue topiramate treatment due to side effects.

Keywords: migraine.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Similar articles

See all similar articles

Cited by

References

    1. Foroozan R, Cutrer FM. Transient neurologic dysfunction in migraine. Neurol Clin 2019;37:673–94. 10.1016/j.ncl.2019.06.002 - DOI - PubMed
    1. Headache Classification Committee of the International Headache Society (IHS) The International classification of headache disorders, 3rd edition (beta version). Cephalalgia 2013;33:629–808. 10.1177/0333102413485658 - DOI - PubMed
    1. Kissoon NR, Cutrer FM. Aura and other neurologic dysfunction in or with migraine. Headache 2017;57:1179–94. 10.1111/head.13101 - DOI - PubMed
    1. Somjen GG Aristides Leão's discovery of cortical spreading depression. J Neurophysiol 2005;94:2–4. 10.1152/classicessays.00031.2005 - DOI - PubMed
    1. Sugaya E, Takato M, Noda Y. Neuronal and glial activity during spreading depression in cerebral cortex of cat. J Neurophysiol 1975;38:822–41. 10.1152/jn.1975.38.4.822 - DOI - PubMed